openPR Logo
Press release

Immune Thrombocytopenia Treatment Market Poised to Incur Steadfast Growth During 2018-2026

Immune Thrombocytopenia Treatment Market Poised to Incur

Immune Thrombocytopenia is an autoimmune disorder that results in an abnormally low level of platelets. Immune thrombocytopenia is asymptomatic bleeding disorders. Symptoms appear only after platelet count is extremely low. Those symptoms include petechiae, skin bruises, gum bleeding and others. According to the National Organization of Rare Diseases, the immune thrombocytopenia incidence in the U.S. is 3.3 per 100,000 adults/year. Estimated annual prevalence 9.5/100,000 in adults and 5.3/100,000 among children. The male population is more significantly affected by immune thrombocytopenia when compared to the female population. Immune thrombocytopenia treatment includes corticosteroids and others symptomatic treatment drugs. FDA approved anti-D for immune thrombocytopenia and designated as an orphan drug. Along with these, anti CD20 antibody, rituximab, Sandimmune, Danocrine, Imuran, Cytoxan, vincristine and other drugs are used as immune thrombocytopenia treatment.

Immune Thrombocytopenia Treatment Market: Drivers and Restraints

A sample of this report is available upon request @ https://www.persistencemarketresearch.com/samples/24328

Orphan drugs may benefit multi-year regulatory exclusivity during which there is no submission of abbreviated NDA /505(b) applications by another manufacturer and it expected fuel immune thrombocytopenia treatment market. Along with these, orphan drugs receive exclusivity period of 7 Years. Exclusivity is meant to encourage investment in research and development by providing innovators with exclusive use for a limited time and expected to boost the immune thrombocytopenia treatment market. This exclusivity operates independently of patent protection and protect the product from the generic competition, even if there is no patent covering the product and it is expected to fuel the growth of immune thrombocytopenia treatment market. In the US, the FDA will not grant final marketing approval to a generic competitor for a New Chemical Entity (NCE) until the expiration of the regulatory exclusivity period that commences upon the first marketing authorization of the reference product. The FDA will accept the filing of an Abbreviated New Drug Application (ANDA) containing a patent challenge one year before the end of this regulatory exclusivity period and boosted the immune thrombocytopenia treatment market. Further, increasing government support in order to advance the research activities is expected to fuel the growth immune thrombocytopenia treatment market. European Union supports manufacturers which take part in the research for rare diseases through its multiannual framework programmes for research and technological development. It offers financial grants to the research proposals and it boosts the immune thrombocytopenia treatment market. Under the FP7, EU granted over €620 million for 120 collaborative projects which are associated with rare diseases and it is expected to fuel immune thrombocytopenia treatment market. All these factors act as a potential driver for the burgeoning growth of immune thrombocytopenia treatment market.

Immune Thrombocytopenia Treatment Market: Overview

The global Immune Thrombocytopenia Treatment market has witnessed robust growth due to increasing demand for devices. Immune thrombocytopenia treatment drugs are granted orphan designation by regulatory bodies has high flexibility over the pricing of drugs. This has given added advantage to developers along with regulatory exclusivity. It is further supported by lack of alternative immune thrombocytopenia treatment options further boosted the growth of immune thrombocytopenia treatment market. Immune thrombocytopenia treatment market has witnessed monopolistic power due to limited players and limited to no competition. Monopolistic nature of the market is expected to offer high immune thrombocytopenia treatment market share to the manufacturers during the forecast period. Along with these, increasing focus of legislative bodies on developing reimbursement policies has fueled the immune thrombocytopenia treatment market.

Immune Thrombocytopenia Treatment Market: Region-Wise Overview

To view TOC of this report is available upon request @ https://www.persistencemarketresearch.com/toc/24328

The global Immune Thrombocytopenia Treatment market can be segmented into the following regions – North America, Latin America, Europe, the Asia Pacific Excluding China, China and the Middle East & Africa. North America immune thrombocytopenia treatment market is expected to remain dominant in the global immune thrombocytopenia treatment market. Europe immune thrombocytopenia treatment market is expected to remain the second dominant region in the global immune thrombocytopenia treatment market. Asia Pacific Excluding China immune thrombocytopenia treatment market is expected to register fast CAGR during the forecast period in global immune thrombocytopenia treatment market. Latin America and Middle East & Africa accounts for a small market share in global immune thrombocytopenia treatment market

Immune Thrombocytopenia Treatment Market: Market Participants

Key participants operating in the Immune Thrombocytopenia Treatment market include GlaxoSmithKline, Novartis AG, Amgen Inc., Emergent BioSolutions, Octapharma USA., Pfizer Inc, Roche Holding AG, Merck & Company, Inc., and others. Players in immune thrombocytopenia treatment market are mainly focusing on collaborations and partnerships to keep pace with the competition and develop new products.

About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Immune Thrombocytopenia Treatment Market Poised to Incur Steadfast Growth During 2018-2026 here

News-ID: 1261589 • Views:

More Releases from Persistence Market Research (PMR)

Virtual Desktop Infrastructure Market Unit Sales to Witness heightened Growth in the Near Future
Virtual Desktop Infrastructure Market Unit Sales to Witness heightened Growth in …
As per findings of a new market research report by Persistence Market Research, the global virtual desktop infrastructure market reached a valuation of nearly US$ 3.5 Bn in 2019, and is anticipated to exhibit a CAGR of around 12% during the forecast period of 2020 to 2030.The adoption of BYOD allows employees to bring their own devices in the organization, which allows then to access company information and applications via virtual desktop infrastructure. With such a BYOD policy, both, employers
Physician Scheduling Systems Market to Generate Profitable Avenues for Existing Companies as Well as New Players
Physician Scheduling Systems Market to Generate Profitable Avenues for Existing …
As per findings of a new market research report by Persistence Market Research, the global physician scheduling system market reached US$ 311 Mn in 2019 and is anticipated to exhibit a healthy CAGR of 14% during the forecast period of 2020 to 2030. Adoption of physician scheduling systems is increasing across the world, as physicians encounter difficulties with increasing administrative tasks and regulations, which affects their ability to offer patient care, and they struggle to sustain their practices. To combat administrative work
Demand for Rfid Electronic Toll Collection System Market from Major End-use Sectors to Increase in the Near Future
Demand for Rfid Electronic Toll Collection System Market from Major End-use Sect …
Many toll collection systems have already been developed with RFID technology, which is used to verify the identity of vehicles. RFID technology can provide new capabilities as well as an efficient method to manage, analyze, and collect information of vehicles at toll plazas. RFID electronic toll collection lanes reduce the traffic at toll booths. Increasing number of RFID lane systems, resulting in increased demand for integration, support services, and maintenance,
Smart Home Cloud Platform Market Unit Sales to Witness heightened Growth in the Near Future
Smart Home Cloud Platform Market Unit Sales to Witness heightened Growth in the …
In a smart home, appliances such as ACs, TVs, geysers, and lights have the potential to communicate with a cloud server. The cloud server communicates with these smart devices by sending and receiving signals through smartphones, laptops, or voice-enabled digital assistant devices.A homeowner can make his/her existing home smart by integrating cloud-based technology with it. Cloud computing enables homeowners to remotely access their home appliances, even if they are miles

All 5 Releases


More Releases for Immune

Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts
Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitors Market Insights 2019, Global and Chinese Scenario is a professional and indepth study on the current state of the global Immune Checkpoint Inhibitors industry with a focus on the Chinese market. The report provides key statistics on the market status of the Immune Checkpoint Inhibitors manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an
Immune Health Supplements: Best Way to Boost Your Immune System
ResearchMoz include new market research report "Global Immune Health Supplements Market Research Report 2019" to its huge collection of research reports. Immune Health Supplements refer to the product which could improve human immune health. The global Immune Health Supplements market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. Learn more Through Sample Report
BOC Sciences Diversifies Immune Checkpoint Inhibitors and Nonspecific Immune Sti …
Headquartered in Shirley, New York, the world’s reputed chemical supplier BOC Sciences announced to diversify its immune checkpoint inhibitors as well as nonspecific immune stimulation targets for scientific research targeting cancer immunotherapy (https://www.bocsci.com/tag/cancer-immunotherapy-36.html) on August 29, 2018. Traditionally, surgery, chemotherapy and radiotherapy are the most widely chosen therapies in cancer treatment. However, in recent years, immunotherapy has attracted increasing attention among the research community. Immunotherapy agents do not directly
Immune Health Supplements Market
The immune health supplements apart from providing resistance to infection and disease, also provide preventive measures that help to maintain immune system. The immune system is a complicated network of various functions, which all together help to prevent against infective agents such as pathogenic bacteria and viruses. Healthy immune system easily recognizes foreign agents. The cells of immune system are different which mainly include the lymphocytes, or T-cells that fight
Immune Check Point Inhibitors Market Immune Check Point Inhibitors Clinical Pipe …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy 1.1 Overview 1.2 History- From Tragedy to Breakthrough Major Immune Checkpoints Proteins 2.1 Role of Cytotoxic T lymphocyte Antigen-4 (CTLA-4) in Cancer Development 2.2 Role of Programed Cell Death Protein 1 (PD1) in Cancer Development Mechanism of Action of Immune Checkpoint Inhibitors 3.1 Cytotoxic T lymphocyte Antigen-4